Similar costs associated with three glaucoma drugs

Article

Two-year follow-up data from patients treated with either latanoprost, travoprost or bimatoprost demonstrates that similar resource consumption outcomes are achieved by all three, as reported by Dr Kobalt and colleagues from European Health Economics in France.

Two-year follow-up data from patients treated with either latanoprost, travoprost or bimatoprost demonstrates that similar resource consumption outcomes are achieved by all three, as reported by Dr Kobalt and colleagues from European Health Economics in France.

The aim of the study was to investigate the long-term resource consumption (four years) related to the use of three intraocular pressure (IOP) lowering treatments, alone or in combination. Complete two-year data was available for 568 subjects. Baseline distribution was 45% latanoprost, 24% travoprost and 31% bimatoprost. Mean age was 65 years and mean time since diagnosis was 4.2 years.

The total mean costs per patient were €1,286. A total of 32.4% of subjects required a treatment change, including 7.3% who needed surgery, resulting in 30% higher costs (€1,521 versus €1,174) resulting from essential hospitalization and surgery.

It was concluded that all three treatments result in similar resource consumption but that treatment may require changing in around 20% of patients.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
© 2025 MJH Life Sciences

All rights reserved.